FDA Approves Optimer's DIFICID™ (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD)

Saturday, May 28, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

- In two CDAD clinical trials, DIFICID was non-inferior to vancomycin in clinical response at the end of therapy and superior to vancomycin in sustained clinical response 25 days post-treatment -

Contacts:

Optimer Pharmaceuticals, Inc.

John D. Prunty, Chief Financial Officer & Senior Vice President, Finance

858-909-0736

Canale Communications, Inc.

Jason I. Spark, Senior Vice President

619-849-6005



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook